Who is an appropriate candidate for this vaccine?

Eligibility should be determined by a licensed clinician based on age, immunization history, and local guidelines. In general, routine use begins at twelve months of age, with catch-up considerations for older individuals depending on documented immunity. Exposure scenarios and public health recommendations may also guide timing. Screen for contraindications, including hypersensitivity to vaccine components. Review potential interactions and clinical circumstances that may warrant deferral. Always follow your jurisdiction’s recommendations for indications and scheduling.

What is the product’s presentation and how is it supplied?

This vaccine is supplied as a lyophilized powder with a separate, clear, colorless solvent for reconstitution. It is a single-dose presentation intended for one individual. Packages may include needles; confirm the exact contents on the label at receipt. Lot and expiration appear on packaging for traceability. Follow your facility’s handling, reconstitution, and documentation procedures as outlined by the manufacturer and local policy.

Can minor illnesses delay scheduling for this vaccine?

A mild illness, such as a cough, cold, or snuffles, typically does not interfere with vaccination. Clinicians may choose to delay if an individual has a high temperature or is acutely unwell. Assess on a case-by-case basis and follow local guidelines for timing. If postponing, coordinate with scheduling staff to minimize missed opportunities while maintaining safety. Document the rationale for any delay in the medical record.

Which contraindications should be reviewed before administration?

Check for hypersensitivity to any vaccine against measles, mumps, or rubella, and to any excipients in the formulation. Review prior adverse events following immunization and relevant allergy history. Consider institutional policies for special populations and exposures. If uncertainty remains, consult product labeling and applicable public health guidance before proceeding. As always, verify eligibility and risk–benefit with a licensed prescriber for each case.

How can clinics streamline handling and documentation?

Establish a standard receiving process with lot and expiry capture at intake. Use barcoded labels when available and confirm label legibility before storage. Train staff on reconstitution steps, observation periods, and documentation in your EHR or registry. Align standing orders with screening tools to reduce variability. For ancillary supplies planning and procurement guidance, see our article on Cannulas And Needles in the resources section.

Is this vaccine used in post-exposure protocols?

Yes, it may be used for post-exposure vaccination as part of public health response, when clinically appropriate and within recommended time frames. Decisions should follow local guidance, epidemiology, and individual risk assessment. Coordinate with your health department for outbreak management and contact tracing support. Ensure documentation of exposure date, lot, and administration site. Avoid making scheduling commitments until inventory and staffing are confirmed.

What comes in each package and are needles included?

Each unit contains a single-dose vial of powder and a separate sterile solvent for mixing. Some packages may include needles; verify the label for the exact contents at receipt. The solvent is clear and colorless. Store and handle per labeling and facility policy. Maintain a small buffer of compatible administration supplies to prevent delays if a package arrives without needles.

You must be logged in to add items to the cart.

Pharmaceuticals

M-M-RVaxPro

M-M-RVaxPro® Vaccine for Clinics

Name: Wholesale M-M-RVaxPro® Vaccine – Clinic Supply
SKU: 100116
Price: 40.99 USD
Availability: InStock

Prescription Medication

$40.99

Description

M-M-RVaxPro is a live attenuated measles, mumps, and rubella vaccine supplied as a lyophilized powder with a separate sterile solvent for injection. Clinics use this preparation to support routine immunization schedules, post-exposure protocols, and outbreak response in eligible individuals aged twelve months and older. We maintain US distribution so your team can plan reliable replenishment.

Med Wholesale Supplies serves licensed clinics and healthcare professionals with authentic, brand-name medical products sourced through vetted distributors.

What M-M-RVaxPro Is and How It Works

M-M-RVaxPro® supports programmatic protection against three vaccine-preventable viral diseases in pediatric and adult workflows as indicated. The vaccine contains live, attenuated measles, mumps, and rubella strains in a stabilised formulation. After administration, the immune system produces specific antibodies to these antigens. On subsequent exposure, immune memory can respond more rapidly, supporting community protection goals when used within recommended programs.

Professional teams typically integrate this product into established immunization schedules, exposure management pathways, and special-risk protocols where appropriate. Candidates should be assessed by a licensed prescriber for suitability and timing. Clinical history and potential contraindications must be reviewed before administration.

Professional Applications

Clinics deploy this vaccine across several operational scenarios. Routine pediatric immunization programs rely on consistent supply for scheduled visits. Catch-up vaccination clinics use it for eligible adolescents and adults based on history. Occupational health teams incorporate it within pre-employment or baseline screening workflows for at-risk roles. Public health units may use it in outbreak response and coordinated exposure follow-up.

Travel medicine services can also include M-M-RVaxPro for travel vaccination when indicated by destination risks and prior immunity. Women’s health and adolescent services often coordinate immunization alongside other preventive care; for HPV protection, see Gardasil 9 as a complementary option. When planning broader preventive services, clinics may schedule related visits around established workflows to improve adherence and coverage.

Key Features

Live attenuated antigens: measles, mumps, and rubella strains.
Clinic-ready format: lyophilized powder with separate solvent for reconstitution.
Single-dose presentation: supports precise inventory rotation.
Clear component separation: vial of powder plus a clear, colorless diluent.
Label clarity: lot and expiry are visible to streamline documentation.
Clinical-class vaccine: MMR immunization vaccine M-M-RVaxPro.

Benefits in Practice

This product fits into standard vaccination rooms and mobile clinics without disrupting throughput. Single-dose packaging reduces partial-use waste and simplifies inventory counts. Consistent component design supports repeatable reconstitution steps across teams. Clear labeling aids scanning and charting, helping maintain accurate records.

The presentation can streamline multi-site implementations where staff rotate across locations. Predictable handling supports nurse-led workflows and minimizes set-up time between appointments. Integration with existing screening questionnaires and standing orders can further standardize administration and observation procedures, reinforcing clinic efficiency.

Composition & Ingredients

The vaccine contains live, attenuated viruses for measles, mumps, and rubella. These antigens are formulated as a lyophilized powder that is reconstituted with the supplied sterile solvent. Excipients and additional components are included as listed by the manufacturer in the official package materials. The diluent is clear and colorless.

Active constituents: live attenuated measles, mumps, and rubella viral strains. Non-active constituents: sterile solvent (diluent) provided for reconstitution. Refer to the manufacturer’s labeling and package insert for the complete list of excipients and any residuals. Always confirm compatibility with clinic policies and local guidance.

Packaging & Supply

The pack is designed for single-patient use and supports standard vaccine room workflows. Each unit typically includes:

A single-dose vial of lyophilized powder
A clear, colorless solvent for mixing with the powder
Needles, if included in the package

Labeling provides lot number and expiration date to support traceability and documentation. Follow local protocols for receiving, storage, and reconstitution. For clinics consolidating immunization inventories, the MMR vaccine M-M-RVaxPro offers familiarity in handling across varied settings, including routine schedules and targeted outreach.

Ordering & Logistics

Create or verify your professional account to access ordering. Sign in to view volume and contract options, request quotes, and assign authorized purchasers. Your team can align replenishment with scheduled clinics to maintain continuity of care. For a broader selection of Rx and biologic items, browse Pharmaceuticals.

Administration supplies planning is often handled alongside vaccine purchasing. For guidance on procurement strategies, review Cannulas And Needles. Build internal checklists for receiving, lot capture, and label verification. Coordinate with your EHR or registry for batch documentation and recall readiness.

Comparable Products

Clinics often standardize vaccine vendors while maintaining alternatives for scheduling flexibility. For complementary vaccines in routine programs, consider Prevenar 13 or Engerix B based on your protocol and patient cohort. Use established screening criteria and local recommendations to select appropriate products.

Pricing & Access

Sign in to view current tiers and contract pricing. Quotes can be aligned with forecasted clinic days or seasonal demand. Our team supports formulary reviews, substitution planning, and multi-site shipment coordination when needed. If you require allocation planning, provide anticipated monthly usage to streamline approvals. M-M-RVaxPro is available to licensed healthcare entities with verified accounts.

Availability & Substitutions

Supply conditions can vary over time. If your preferred presentation is temporarily constrained, discuss acceptable substitutes with your clinical leadership before ordering. Align any changeovers with your local guidance and documentation requirements. We will advise if packaging updates or lot transitions affect barcodes or scanning workflows. No restock timing is guaranteed; plan buffer inventory for scheduled clinic days when possible.

Authoritative Sources

See the following resources for class-level information and guidance:

For broader preventive care planning in women’s health, you may also review Nexplanon Implant as part of visit coordination in integrated clinics.

Professional Notes & Precautions

Review patient history for prior vaccine reactions and hypersensitivity. Hypersensitivity to any vaccine against measles, mumps, or rubella, or to any excipients, is a contraindication. Minor illness, such as a cough, cold, or snuffles, generally does not interfere with vaccination. Clinicians may delay vaccination in individuals who are acutely unwell or febrile. Follow local recommendations on age eligibility, special populations, and exposure management.

Store and handle according to manufacturer guidance and institutional policy. Ensure appropriate documentation of lot, expiry, and site-of-care protocols. Train staff on reconstitution steps and observation procedures consistent with clinic standards.

Ready to align your next immunization clinic? Contact our team to schedule supply, with temperature-controlled handling when required and tracked US delivery.

Frequently Asked Questions

Who is an appropriate candidate for this vaccine?
Eligibility should be determined by a licensed clinician based on age, immunization history, and local guidelines. In general, routine use begins at twelve months of age, with catch-up considerations for older individuals depending on documented immunity. Exposure scenarios and public health recommendations may also guide timing. Screen for contraindications, including hypersensitivity to vaccine components. Review potential interactions and clinical circumstances that may warrant deferral. Always follow your jurisdiction’s recommendations for indications and scheduling.
What is the product’s presentation and how is it supplied?
This vaccine is supplied as a lyophilized powder with a separate, clear, colorless solvent for reconstitution. It is a single-dose presentation intended for one individual. Packages may include needles; confirm the exact contents on the label at receipt. Lot and expiration appear on packaging for traceability. Follow your facility’s handling, reconstitution, and documentation procedures as outlined by the manufacturer and local policy.
Can minor illnesses delay scheduling for this vaccine?
A mild illness, such as a cough, cold, or snuffles, typically does not interfere with vaccination. Clinicians may choose to delay if an individual has a high temperature or is acutely unwell. Assess on a case-by-case basis and follow local guidelines for timing. If postponing, coordinate with scheduling staff to minimize missed opportunities while maintaining safety. Document the rationale for any delay in the medical record.
Which contraindications should be reviewed before administration?
Check for hypersensitivity to any vaccine against measles, mumps, or rubella, and to any excipients in the formulation. Review prior adverse events following immunization and relevant allergy history. Consider institutional policies for special populations and exposures. If uncertainty remains, consult product labeling and applicable public health guidance before proceeding. As always, verify eligibility and risk–benefit with a licensed prescriber for each case.
How can clinics streamline handling and documentation?
Establish a standard receiving process with lot and expiry capture at intake. Use barcoded labels when available and confirm label legibility before storage. Train staff on reconstitution steps, observation periods, and documentation in your EHR or registry. Align standing orders with screening tools to reduce variability. For ancillary supplies planning and procurement guidance, see our article on Cannulas And Needles in the resources section.
Is this vaccine used in post-exposure protocols?
Yes, it may be used for post-exposure vaccination as part of public health response, when clinically appropriate and within recommended time frames. Decisions should follow local guidance, epidemiology, and individual risk assessment. Coordinate with your health department for outbreak management and contact tracing support. Ensure documentation of exposure date, lot, and administration site. Avoid making scheduling commitments until inventory and staffing are confirmed.
What comes in each package and are needles included?
Each unit contains a single-dose vial of powder and a separate sterile solvent for mixing. Some packages may include needles; verify the label for the exact contents at receipt. The solvent is clear and colorless. Store and handle per labeling and facility policy. Maintain a small buffer of compatible administration supplies to prevent delays if a package arrives without needles.

Specifications

Main Ingredient:
Manufacturer: MDS
Drug Class:
Generic Name:
Package Contents: 1 Vial
Storage Requirements: Storage: 2-8 ºc
Main Usage:

Here to help

Questions about ordering, delivery or products? You can email our team here or call now at 1-800-630-9757 and be connected with your dedicated Account Manager

International Shipping

Seamless delivery across the world

Easy Returns

Flexible solutions with our 30 day return policy

Secure Payments

Order confidently with private security network